Details for Patent: 8,962,629

Which drugs does patent 8,962,629 protect, and when does it expire?

Patent 8,962,629 protects RINVOQ and is included in one NDA.

This patent has one hundred and twenty-eight patent family members in forty-one countries.

Summary for Patent: 8,962,629

Title:	Tricyclic compounds
Abstract:	The invention provides a compound of Formula (I) ##STR00001## pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Inventor(s):	Wishart; Neil (Jefferson, MA), Argiriadi; Maria A. (Wayland, MA), Calderwood; David J. (Framingham, MA), Ericsson; Anna M. (Shrewsbury, MA), Fiamengo; Bryan A. (Worcester, MA), Frank; Kristine E. (Grayslake, IL), Friedman; Michael M. (Brookline, MA), George; Dawn M. (Charlton, MA), Goedken; Eric R. (Worcester, MA), Josephsohn; Nathan S. (Boston, MA), Li; Biqin C. (Southborough, MA), Stewart; Kent D. (Gurnee, IL), Wallace; Grier A. (Sterling, MA), Wang; Lu (Northborough, MA), Woller; Kevin R. (Antioch, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	12/481,028
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,962,629
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 8,962,629

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No				Y		TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No				Y		TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No				Y		TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No				Y		TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No				Y		TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-002	Jan 14, 2022		RX	Yes	No				Y		TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS

International Family Members for US Patent 8,962,629

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072086
Argentina	079234
Argentina	114947
Australia	2009257602
Australia	2010326108
Australia	2016201825